ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 40.21K shares, a 91.18% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 7.83K shares, a 95.51% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 358.13K shares, a 54.13% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 146.52K shares, a 29.44% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.13M shares, a 22.70% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.47M shares, a 39.40% decline from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 2.42M shares, a 341.47% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 548.77K shares, a 109.80% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 40.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 552.69K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 7.83K shares 10-Q · filed 2026-05-15 | 968.41K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 358.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 1.13M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 146.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.56M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 455.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.62M shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 174.25K shares 10-Q · filed 2025-05-14 | 1.48M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 780.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 1.47M shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 207.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 1.28M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 322.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 1.55M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 157.71K shares 10-Q · filed 2024-05-09 | 2.08M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 595.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 2.42M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 473.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 1.79M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 851.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.89M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 502.69K shares 10-Q · filed 2023-05-15 | 1.04M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | -39.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 548.77K shares 10-K · filed 2023-03-23 |
| 2022-09-30 | 573.73K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 615.05K shares derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | 3.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 110.69K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 11.35K shares 10-Q · filed 2022-05-12 | 170.95K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 26.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 261.57K shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 69.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | 63.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 101.96K shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |